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Abstract
Identification of biomarkers to recognize individuals
with Barrett’s esophagus (BE) predisposed to develop
malignancy is currently a pressing issue. We utilized
gene expression profiling to compare molecular signa-
tures of normal esophagus and stomach, BE, and ade-
nocarcinoma (AC) to identify suchpotential biomarkers.
Over 22,000 genes were analyzed by oligonucleotide
microarrays on 38 unique RNA. Unsupervised and
supervised clusterings were performed on a subset of
2849 genes that varied most significantly across the
specimens. Unsupervised clustering identified two
discernable molecular BE profiles, one of which was
similar to normal gastric tissue (‘‘BE1’’), and another
that was shared by several of the AC specimens
(‘‘BE2’’). TheBE1 profile included expression of several
genes that have been described as tumor-suppressor
genes, most notably trefoil factor 1 (TFF-1). The BE2
profile included expression of genes previously found
overexpressed in cancers, such as carboxylesterase-2
(CES-2). IHC demonstrated the loss of TFF-1 late in the
progression of BE to AC. It also revealedCES-2 as being
upregulated in AC documented to have arisen in the
presence of BE. These potential biomarkers, as well as
the relative expression of genes from BE1 versus those
from BE2, may be validated in the future to aid in risk
stratification and guide treatment protocols in patients
with BE and associated AC.
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Introduction
Adenocarcinoma (AC) of the esophagus or esophagogas-
tric junction (EGJ) has the most rapidly rising incidence of
all malignancies in Western nations [1,2]. In the United
States and United Kingdom, these carcinomas combine to
rank as the fifth most prevalent cancer [3]. This phenom-
enon has been shown to correspond with an increase in the
incidence of specialized intestinal cell metaplasia of the distal
esophagus, or Barrett’s esophagus (BE) [4]. BE is recognized
as the precursor lesion to AC of esophageal or EGJ origin.
Approximately 12% to 18% of patients who undergo upper
endoscopy for symptoms of gastroesophageal reflux disease
are observed to have BE, and it is estimated that between
0.5% and 2.0% of adults in the United States and Western
Europe have BE [5–7]. Survival rates from BE-associated
AC are poor (<10% at 5 years), with the mortality rate often
matching the incidence rate [8]. Only early diagnosis and
aggressive treatment strategies, such as esophagectomy,
have been shown to alter the course of this disease. Thus,
a better understanding of the genetic changes that accom-
pany the evolution of normal mucosa to AC, through BE, is
desired in order to gain insight into this complex disorder and
achieve improved outcomes.
Barrett’s metaplasia can progress to low-grade dysplasia
(LGD), high-grade dysplasia (HGD), and, eventually, AC. Dys-
plastic changes occur in a minority of cases of BE, and AC
develops in only 0.2% to 2.0% of patients. However, with the
use of current clinical tools, it is difficult to predict the popula-
tions in which metaplasia will advance to neoplasia. Charac-
terization of biomarkers that identify a predisposition of certain
individuals with BE to the development of dysplasia and/or
malignancy is eagerly awaited to advance the management of
patients with this lesion.
Expression profiling using microarray technology is antici-
pated to aid in the discovery of expression signatures that may
have clinical utility applicable to BE-associated AC. Microarray
analysis has been utilized in several recent reports from Asia to
examine gene expression profiles in gastric adenocarcinoma
(GC) [9–11]. These have been promising in that they have led
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to further understanding of the molecular basis of GC, and
the discovery of expression profiles and candidate bio-
markers that may have practical value. GC, particularly of
the intestinal type, commonly arises from gastric intestinal
metaplasia and is regarded by many as having biologic
properties similar to BE-associated AC. Microarray technol-
ogy has been utilized to explore global expression profiles of
BE and its associated malignancies in two previous publica-
tions [12,13]. These showed some promise in the classifica-
tion of esophageal AC and premalignant disease; however,
they were limited by relatively small sample size, lack of
inclusion of expression results for normal tissue, and incom-
plete exploration of the genome. Two additional recent
studies utilized microarray technology to compare gene
expression profiles of BE to normal tissues [14], and BE with
and without exposure to acid reflux [15], but neither included
malignant tissues in their analyses.
Herein, we performed a comprehensive comparison of the
gene expression profiles of all relevant tissue subtypes,
including normal esophagus and stomach; BE; and AC of
the esophagus, EGJ, and stomach. Moreover, we used xeno-
grafted human tumors to profile optimally enrichedsamples for
neoplastic cells. These xenografted tumors are genetically
stable and are a good representation of the primary tumors
fromwhich they are derived [16,17]. Moreover, homogeneous
human epithelial neoplastic cells in the xenografted tumors
supported by the mouse stroma provide optimal samples for
human probes. Confirmation of alterations in gene expression
was performed by immunohistochemical staining of a large
cohort of tumor specimens assembled on tissue microarrays
(TMAs).Our analysis leads to thedefinition of twounique gene
expression profiles within BE, one of which was shared to a
significant extent by normal gastric tissue, and another was
shared by several of the AC specimens. This study suggests
that molecular definition of BE is possible and, with further
validation, may have practical utility for the prediction of the
aggressive course of this precancerous condition.
Materials and Methods
Tissue Samples
Tissue samples were obtained from patients who had
undergone resections for primary esophageal, EGJ, or gas-
tric AC. These samples included fresh tissues for xeno-
grafting in nude mice, fresh-frozen tissue stored in liquid
nitrogen, and formalin-fixed paraffin-embedded tissue.
Tumors were collected from the Department of Pathology
at the University of Virginia Health System, Indiana Univer-
sity, Johns Hopkins University, and from Siena, Italy. The
University of Virginia Human Investigation Committee (IRB)
approved the use of human tissues in this study.
Xenografting
Small pieces of primary human esophageal, EGJ, and
gastric tumor tissue were soaked in Matrigel (Collaborative
Biomedical Research, Amherst, MA) and then implanted
subcutaneously into the flanks of immunodeficient mice
(nu/nu from Harlan, Indianapolis, IN or SCID from Charles
River, Wilmington, MA) for xenograft growth, as previously
reported [18]. First-passage tumors were harvested when
their diameter reached f1 cm.
Microarray Hybridization and Data Analysis
RNA extraction, cRNA synthesis, and GeneChip hybridi-
zations were preformed as described previously [19]. Raw
data from the GeneChips were processed using MAS5.0
(Affymetrix, Santa Clara, CA), scaled to an average differ-
ence value of 200 and collated in Microsoft EXCEL for further
analysis. Agglomerative clustering was performed using
Cluster, and the results of clustering were visualized in
Treeview [20]. The standard deviation from the mean of
each gene’s expression value across samples was used as
a measure of variability to select the genes for clustering. For
the data presented in Figure 1, a value of 250 was used.
Supervised learning was performed using GeneCluster2
(http://www.broad.mit.edu/cancer/software.html) [21]. Pro-
cessed GeneChip hybridization data were imported to Gene-
Cluster2 in .gct format and the class of each sample was
specified. For classification, a k-nearest neighbors (k-NN)
algorithm was used, specifying k = 3. Class predictions were
calculated for variable numbers of genes in increments of 10
(from 10 to 100). Feature summary data (i.e., from the subset
of the genes used in class prediction) were exported from
GeneCluster2 and visualized in Treeview. A signal-to-noise
(S2N) metric was used to identify 20 genes per class for each
of the four groups of samples, and also exported and
visualized in Treeview. To identify genes specifically
expressed in a group of samples, we used EXCEL to perform
gene ranking. The difference in expression was first exam-
ined using the fold ratios of the average of each gene’s
expression in each group. In the case of BE, we also
specified that the average expression of a gene must be
<50 in samples of stomach and esophageal mucosa and
>200 in BE. Only those genes with a fold change >2 in BE
versus all other samples were selected (n = 21).
TMAs
Targeted tissues (tumor and normal) were marked on
H&E-stained slides corresponding to their paraffin blocks.
One to four 0.6-mm cores from each tumor were obtained
from donor blocks using a manual microarray device
(Beecher Instruments, Silver Spring, MD) and inserted into
recipient paraffin blocks in gridded arrays. The TMAs were
sectioned at 4 mm thickness and placed on charged slides.
Immunohistochemistry (IHC)
TFF-1 Following application of a monoclonal antibody to
TFF-1 (Zymed Laboratory, San Francisco, CA), as described
previously [18], expression was evaluated by our pathologist
(C.A.M.) using a semiquantitative scoring system. As stain-
ing intensity for TFF-1 did not greatly vary in cells exhibiting
staining, the extent of cell staining was scored on a percent-
age basis: 0 (<1%, ‘‘negative’’), 1+ (1–25%, ‘‘weak’’), 2+
(26–50%, ‘‘moderate’’), 3+ (51–75%, ‘‘strong’’), and 4+
(76–100%, ‘‘marked’’). In evaluating tumors, all cancer cells
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in the specimen were evaluated; in non-neoplastic gastric
mucosa, only foveolar neck and surface mucous epithelial
cells were evaluated; in metaplastic Barrett’s mucosa, only
epithelial cells in the superficial portions of the glands and the
surface epithelial cells were evaluated.
CES-2 The primary antibody was generated by Genemed
Synthesis, Inc. (South San Francisco, CA), as presented
previously [22]. For immunostaining, streptavidin–biotin
complex IHC was performed using an i6000 automated
staining system (BioGenex, San Ramon, CA) at room
Figure 1. Agglomerative clustering analysis. Analysis of the molecular profiles generated using agglomerative clustering demonstrating a strong relationship
between normal, neoplastic, and BE specimens (panel A). The far right column lists representative genes predominantly expressed in each of the tissue types
(panel B). ST = stomach; BE = Barrett’s esophagus; E = esophagus; AC = adenocarcinoma; CL = cell line.
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temperature without antigen retrieval. The protocol was as
follows: dewax, 10 minutes; peroxide block, 20 minutes;
biotin block, 20 minutes; power block, 20 minutes; CES-2
(1:150), 1 hour; link, 30 minutes; label, 20 minutes; 3,3V-
diaminobenzidine tetrahydrochloride, 5 minutes; and he-
matoxylin, 1 minute. The negative controls were omission
of the primary antibody or antibody preadsorption with its
cognate peptide (1 mg/ml) overnight at 4jC.
CES-2 expression was evaluated by two pathologists
(H.Z. and W.Z.) using a semiquantitative scoring system.
The intensity of staining was scored as 0 (negative), 1 (weak),
2 (medium), or 3 (strong). The extent of staining was scored
as 0 (0%), 1 (1–25%), 2 (26–50%), 3 (51–75%), or 4
(76–100%), according to the percentages of the positive-
staining tumor cells within each specimen on the tissue
array. The sum of the scores for the intensity and extent of
staining was determined. Tissues having a final staining
score of less than 2 were considered ‘‘negative,’’ and tissues
having a score of greater than 2 were considered ‘‘positive.’’
A sum score of 2 to 3 was considered ‘‘weak’’ (1+); 4 to 5 was
‘‘moderate’’ (2+); and 6 to 7 was ‘‘marked’’ (3+).
CD-13 Prior to avidin–biotin immunoperoxidase, slides
were placed in citrate buffer and treated with microwave heat
for 20 minutes. The monoclonal antibody to CD-13 (clone
38C12, 1:50 dilution; Novocastra Laboratories, Newcastle
upon Tyne, UK) was applied for 1 hour at room temperature.
Staining was evaluated by one pathologist (H.F.F.) and
scored as 0 (‘‘negative’’), 1+ (1–10% positive cells, ‘‘weak’’),
2+ (11–50%, ‘‘moderate’’), or 3+ (>50%, ‘‘marked’’).
Results
Gene Expression Profiles
Total RNA from 38 tissue specimens was hybridized on
oligonucleotidemicroarrays containing probe sets for approxi-
mately 22,000 genes. The specimens included biopsies of
normal esophagus (n = 2), normal stomach (n = 5, including
one set of normal gastric tissue pooled from a total of four
subjects), BE (n = 4), primary human esophageal and gastric
AC (n = 5), and xenografted human esophageal and gastric
AC (n = 20). Clinical and pathologic information on each of
the specimens is detailed in Table 1. The primary cancers
and xenografts studied were each derived from unique indi-
viduals with the exception of G208 and X71, which originated
from the same patient. One xenografted specimen (X155)
was hybridized in duplicate to determine the reproducibility
of the assays. In addition, three separate human gastric
AC-derived cell lines were included in the analysis.
Agglomerative Clustering Analysis
To reveal distinctions between individual samples, ag-
glomerative clustering was performed on a subset of
2849 genes that varied most significantly across the speci-
mens. Clustering demonstrated a strong relationship be-
tween the normal specimens, and a similarly strong
relationship among the AC specimens. The BE specimens
were also highly associated with one another (Figure 1). The
reproducibility of this analysis was underscored by the
significant coclustering of duplicate samples studied from
the same patient (X155a and X155b), as well as the almost
identical coclustering of a xenograft (X71) and primary tumor
sample (G208) from the same patient.
As expected, normal esophageal specimens exhibited
expression of genes specific to stratified squamous epithelial
cells. These included multiple cytokeratins, specifically
CK-1, CK-4, CK-5, CK-6a, CK-6b, and CK-13 to CK-17
(Figure 1) [23,24]. Other than CK-17, which was expressed
in some of the AC specimens, none of these cytokeratin
genes was expressed in any of the normal stomach or AC
specimens. Additionally, several members of the EF hand
calcium binding proteins, notably S100A2, S100A7 to
S100A9, S100A11, and S100A14, were found to be highly
Table 1. Characterization of Cases Analyzed by Oligonucleotide Microarray
Hybridization.
Case Age Site Histology TNM Stage Grade Barrett’s
Normals
N334 59 E N
N445 74 E N
N4 57 S N
N257 68 S N
N285 68 S N
N334 59 S N
NP 50 S N
Barrett’s esophagus
B1 69 E Y
334 59 E Y
B5 66 E Y
B6 60 E Y
Xenografts
X11 67 EGJ D II PD N
X20 66 EGJ I T1N1M0 IIB MD Y
X43 78 MID I T4N1M0 IV PD N
X46 70 EGJ I T4N1M0 IV MD Y
X49 64 EGJ D T3N1M0 III PD Y
X51 44 EGJ I T4N1M1 IV MD N
X55 62 EGJ I T2N1M0 IIB MD Y
X56 70 EGJ I T3N1M0 IIIA MD Y
X57 64 EGJ I T3N1M1 IV MD N
X58 64 CARD I T4N0M0 IIIA PD N
X65 46 DIST I T3N1M0 IIIA PD N
X71 64 MID M T2N1M0 IIB PD N
X75 60 E I T3N1M0 III MD Y
X76 60 CARD I T3N1M0 IIIA WD N
X79 72 E I T2N0M0 IIA MD Y
X102 72 DIST I T3N1M0 IIIA UD N
X116 59 EGJ I T3N1M0 MD ND
X143 48 E I T3N1M0 III PD Y
X155 62 MID D T2N2 IIIA MD ND
X156 77 EGJ I T2N0M0 IB MD ND
Primary tumors
G208 60 CARD I T3N1M0 IIIA WD N
G234 58 E I T4N0M0 III MD N
G280 68 CARD D T3N2M0 IIIB PD N
G296 42 CARD D T3N1M0 IIIA PD Y
G328 84 EGJ M T3N1M0 IIIA PD Y
E = esophagus; S = stomach; EGJ = gastroesophageal junction; CARD =
gastric cardia; MID = midstomach; DIST = distal stomach; WD = well-
differentiated; MD = moderately differentiated; PD = poorly differentiated;
UD = undifferentiated; ND = not determined.
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expressed in normal esophageal specimens. Again, these
genes were not expressed in any of the normal stomach or
AC samples in our analysis. Similarly, specimens derived
from normal stomach expressed genes known to be specific
to this tissue, including gastric intrinsic factor, gastric lipase,
gastrin, and progastricin (Figure 1) [25–27].
Three types of esophageal and gastric AC specimens
were studied: primary human tumors, xenografted human
tumors, and human gastric cancer cell lines. These were
found to cluster together, separate from normal and BE
tissue samples. Primary tumors and xenografts were either
clustered on a subbranch that also subtended the normal
and BE cases, or entirely within a separate branch. Of the
specimens in the latter branch, a subset was shown to
cluster directly with the cell lines. This tight association
appeared to be driven by the high relative expression of
genes involved in cell cycle progression and cellular repli-
cation, including MCM2, PCNA, and UBCH10, each of which
has been previously described as a marker of aggressive
tumor invasion and poor prognosis in various malignancies
[28–36]. Statistical comparison of the clinical features of the
tumors that clustered in each of the subbranches, such as
TNM stage, pathologic grade, or mortality, did not reveal any
distinct differences among these groups.
BE specimens expressed two clearly discernable pro-
files, one of which was shared to a significant extent by the
normal stomach mucosal biopsy samples (termed ‘‘BE1’’;
Figure 1) and another that was shared by a subgroup of AC
samples (termed ‘‘BE2’’; Figure 1). BE1 included several
genes that have been implicated as tumor-suppressor
genes, most notably trefoil factor 1 (TFF-1) [18,37–46].
BE2 included several genes that have been previously
shown to be overexpressed in cancer such as carboxyl-
esterase 2 (CES-2), galectin-4, glycoprotein A33, and liver–
intestine cadherin (LI cadherin) [13,22,47–49]. Interestingly,
this subgroup of cancers that shared the BE2 profile
also expressed intestinal-like genes such as A33 and
LI cadherin, and are unique from the highly proliferative
subset. We also identified genes that were coexpressed
between BE and normal esophagus, notably CK-4, CK-5,
CK-6a, CK-6b, and CK-13 to CK-16, as well as S100A2 and
S100A7 to S100A9. Thus, BE is molecularly similar to
stomach and, in part, esophagus, as well as a small sub-
group of the carcinomas.
Subgroup analysis was performed to compare the ex-
pression profiles of all BE and AC specimens combined with
that of all normal esophageal and stomach tissues. Genes
were manually ranked by both foldchange and t-test. Several
genes emerged as being highly expressed in the BE and
AC specimens, but showed a low level of expression in nor-
mal esophagus and stomach. These included claudin 3,
RhoGTPase 8, highly expressed in cancer/rich in heptad
repeats (HEC), and E2F-3.
Supervised Classification of Tissue Specimens
The results of agglomerative clustering suggested that
specimens representing either unique cell types (e.g.,
normal esophagus versus stomach) or normal versus meta-
plastic (e.g., BE) versus neoplastic lesions (e.g., AC) could
be readily differentiated. To more carefully evaluate the
molecular differences between tissues and cell types, a su-
pervised learning analysis was performed.
For these experiments, the group membership of each
specimen was defined, and a k-NN algorithm was used to as-
sess the extent to which specimens in the four groups could
correctly be classified by leave-out-one cross-validation
(LOOCV). Supervised classification with a 100-gene classi-
fier correctly predicted all of the samples according to their
specified group membership, confirming and extending the
results of unsupervised clustering. Although the k-NNmethod
used different genes to build a predictive model during each
successive loop of the LOOCV procedure, the same genes
were typically common to each model.
The 18 genes used in all models are depicted in Figure 2A,
and the top 20 genes that best discriminated each of the
groups by a S2N metric are depicted in Figure 2B. Although
we could classify BE from all of the other tissue samples
by supervised classification, we found very few instances
of genes with BE unique expression. Genes that were
strongly expressed in these lesions were also typically ex-
pressed to some degree in one or more normal stomach or
AC specimens.
In an effort to identify sequences that were most predom-
inantly expressed in BE, genes weremanually ranked accord-
ing to their near-uniform expression in BE, selecting against
those with expression in normal tissues to the highest extent
possible (see Materials and Methods). Expression in AC was
also selected against; however, this criterion was less strin-
gent. This analysis yielded 21 genes as highly and near-
uniformly positive in all BE specimens, with low expression
in most AC specimens (Table 2). Many of these have been
previously described as being specific to human intestinal
epithelium [50–57]. Genes with high expression in BE that
exhibited low or absent expression in 21 of 25 AC specimens
included sucrase– isomaltase and microsomal aminopep-
tidase (CD-13). Other genes, such as fatty acid binding protein
1 (FABP-1) and meprin Aa (PABA peptide hydrolase),
exhibited low or absent expression in 17 of 25 AC specimens.
IHC
To extend the results of the expression profiles generated
by the microarray analysis, immunohistochemisty was per-
formed. One gene from each of the two sets of molecular
profiles previously described as expressed in BE (from BE1,
TFF-1; from BE2, CES-2) was selected for further study. An
additional gene found in the profile unique to BE (CD-13) was
included in this analysis.
TFF-1 Staining with monoclonal antibody to TFF-1 was
performed on 15 esophageal biopsy specimens demonstrat-
ing a variety of epithelial subtypes, including normal squa-
mous, gastric cardia-like, specialized intestinal metaplasia
(BE), and BE with LGD or HGD. In addition, primary esoph-
ageal and gastric AC tumor specimens procured from a
variety of geographic regions including the University of
Virginia, Indiana University, Johns Hopkins University, as
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well as from Siena, Italy, were examined on TMA analysis.
Collectively, these TMAs contained 266 primary tumor speci-
mens and 42 xenografted specimens from 293 individual
patients. Among these were 16 tissue specimens included in
the oligonucleotide microarray hybridization analysis. Pri-
mary tumor sites included the esophagus (n = 30), EGJ
(n = 79), and stomach (n = 114), which were subdivided
in 46 cases into the proximal stomach (n = 8), midstomach
(n = 21), and distal stomach (n = 17).
In examining the representative tissue biopsies, gastric
cardia-like tissue was visualized in eight specimens and
stained markedly positive for the presence of TFF-1 in each.
BE without dysplasia stained markedly positive in three of
five cases, and each of the remaining two cases stained
at least weakly positive. In the five cases of BE with LGD
or HGD, four stained markedly positive and one stained
strongly positive. Staining intensity did not correlate with
degree of dysplasia (Figure 3).
In contrast, staining for TFF-1 was found to be negative or
weakly positive in 248 (84.6%) of the 293 AC specimens on
the TMAs: 213 demonstrated an IHC score of 0, and 35 had
an IHC score of 1 (Table 3). Only 45 (15.4%) of the AC
specimens stained at least moderately positive for the pres-
ence of TFF-1. This ratio was consistent across all anatomic
sites of tumor origin (Table 3). As histopathologic grade
worsened, TFF-1 expression decreased somewhat: well-
differentiated (n = 12), moderately differentiated (n = 33),
and poorly differentiated (n = 88) tumors had negative or
weak expression in 75.0%, 81.8%, and 84.1% of specimens,
respectively. However, this trend was not shown to be sta-
tistically significant (P = .73).
Of the 119 combined cases of esophageal, EGJ, and
proximal gastric ACs, 13 were known definitively to have
arisen in association with biopsy-proven BE. Subgroup anal-
ysis of tissue from these cases demonstrated that nine
(69.2%) had negative or weak staining for the presence of
TFF-1. In the remaining 106 cases, for which association
with BE was either not present or unknown, 84 (79.2%) had
negative or weak staining. This difference was not shown to
be statistically significant (P = .41).
CES-2 TMAs that included 281 primary tumor specimens
and 42 xenografted specimens from 306 individual patients
were studied with an antibody to CES-2. Among these were
Figure 2. Supervised classification of tissue specimens. Tissue samples were divided into four groups (E = esophagus, ST = stomach, BE = Barrett’s esophagus, GC
= adenocarcinoma) and subjected to supervised learning using k-NN. The 18 genes in panel A are those that were used in all models to correctly predict all of the
tissue samples correctly. Panel B depicts the 20 genes per group best correlated with the distinction between the four types of tissue with a S2N ranking metric.
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17 tissue specimens included in the oligonucleotide micro-
array hybridization analysis. Primary tumor sites included the
esophagus (n = 28), EGJ (n = 80), and stomach (n = 121),
which were subdivided into 54 cases into the proximal stom-
ach (n = 9), midstomach (n = 21), and distal stomach (n = 24).
As expected, CES-2 staining was weak in the represen-
tative normal gastric specimens. All of the BE tissues that
were examined demonstrated at least weak staining for
CES-2 (Figure 3). This was expected, given the high level
of expression of CES-2 by the BE specimens in the micro-
array analysis.
At least moderately positive staining for CES-2 was seen
in 176 (57.5%) of all AC specimens combined (Table 3).
There was no variation across anatomic sites: 15 (53.6%)
esophagus, 47 (58.7%) EGJ, and 70 (57.8%) gastric (Table 3).
Well-differentiated (n = 11) and moderately differentiated
(n = 34) tumors had moderate to marked expression in
63.6% and 67.6% of specimens, respectively. However,
poorly differentiated (n = 86) tumors had moderate to
marked expression in only 41.8%. The difference between
well- and moderately differentiated tumors, compared to
poorly differentiated tumors, was shown to be statistically
significant (P = .026). Of 95 Italian specimens, 47 (49.5%)
demonstrated at least moderate positive staining, compared
with 129 (61.1%) of 211 American specimens. This was not
shown to be statistically significant (P = .056).
Of the 114 combined cases of esophageal, EGJ, and
proximal gastric ACs, 23 definitively arose in association with
biopsy-proven BE. Subgroup analysis of tissue from these
cases demonstrated that 18 (78.3%) stained either moder-
ately or markedly for the presence of CES-2 by IHC. In the
remaining 91 cases, for which association with BE was either
not present or unknown, 42 (46.2%) stained either moder-
ately or markedly positive. This difference was shown to be
statistically significant (P = .022).
CD-13 Staining of esophageal and gastric epithelial cells
was negative throughout for CD-13, whereas duodenal
epithelium and BE stained markedly positive (Figure 3).
Histiocytes and stromal cells in each of these types of
specimens stained positive as well. Ten (71.4%) of 14 AC
specimens with gene expression profile analysis demon-
strated either negative (n = 8) or weak (n = 2) staining. Only
four (28.6%) stained either moderately or markedly positive
(IHC score z2) for the presence of CD-13. These results
were consistent with those of the oligonucleotide microarray
hybridization analysis, which demonstrated that CD-13 ex-
pression was high in BE, with decreased expression in both
normal and neoplastic specimens.
Discussion
Agglomerative clustering analysis demonstrated a strong
relationship between the normal esophageal and gastric
specimens, as well as a similarly strong relationship among
the AC specimens. Normal esophageal specimens exhibited
expression of genes specific to stratified squamous epithelial
cells, and specimens derived from normal stomach ex-
pressed genes known to be specific to this tissue as ex-
pected. Primary tumors and xenografts demonstrated a high
relative expression ofmultiple known oncogenes. Supervised
classification of tissue specimens confirmed that the sepa-
rations observed by agglomerative clustering were primarily
driven by the intrinsic transcriptional program of epithelial
cells in each specimen, rather than from contamination of
specimens by inflammatory or stromal cells.
The BE specimens were highly associated with one
another on agglomerative clustering, with a unique gene
expression profile distinct from normal and AC specimens.
Supervised classification demonstrated these same gen-
eral features of BE, with shared expression of genes with
normal columnar gastric epithelium, and, to a lesser extent,
with stratified squamous esophageal epithelium. The 21 se-
quences that were relatively unique to BE contained several
genes known to be expressed in intestinal epithelium.
The presence of two clearly discernable profiles: ‘‘BE1,’’
which was shared by stomach mucosal samples, and
‘‘BE2,’’ which was shared by AC samples, is consistent
with BE occurring as an intermediate step in the normal
mucosa-to-AC sequence. One could hypothesize that only
a fine balance between the expression of tumor-suppressor
genes from BE1 and the expression of oncogenes from
BE2 limits the malignant potential of any individual BE
lesion. In this exploratory study, none of the four BE spe-
cimens analyzed with the microarray technique contained
any degree of dysplastic epithelium. Further analyses are
warranted to examine an increased number of BE speci-
mens with varying degrees of dysplasia, as well as from
some individuals who have progressed to AC. The relative
expression of BE1 and BE2 sequences in these varying
circumstances may eventually prove useful in risk stratifi-
cation of these patients.
TFF-1
As was predicted by the results of the microarray analy-
sis, IHC demonstrated absent or minimal expression of the
Table 2. Genes Predominantly Expressed in Barrett’s Esophagus.
Microsomal aminopeptidase
Sucrase– isomaltase
Hepatocellular carcinoma antigen gene 520
Enterokinase
FABP-1
Meprin A (alpha PABA peptide hydrolase)
GW112
Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 (CHST5)
Hypothetical protein FLJ22800 (FLJ22800)
Claudin 15
MIP-1 delta
Breast cancer resistance protein (BCRP)
FLJ22893 fis, clone KAT04792
MGC:12387
Liver – intestine cadherin
Mucin 5, subtype B, tracheobronchial
Vanin 1
Cystic fibrosis transmembrane conductance regulator, ATP-binding cassette
(subfamily C, member 7) (CFTR)
Zinc finger protein (ZNFB7)
Caudal type homeobox transcription factor 1 (CDX1)
Retinoic acid receptor responder (tazarotene-induced) 1
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TFF-1 protein product in the vast majority (84.6%) of the
293 combined esophageal and gastric AC specimens. In ad-
dition, staining of normal stomach and BE, with and without
dysplasia, confirmed an abundant expression of TFF-1 in
these tissues. This is the first report of TFF-1 loss being
involved in the transformation of BE to AC.
TFF-1 has been extensively characterized as a tumor-
suppressor gene in gastric AC, with decreased expres-
sion demonstrated at both the mRNA and protein levels
[18,37–39,41–43,45]. In addition, TFF-1 knockout mice have
been observed to develop gastric lesions [40]. The results of
this study indicate that loss of TFF-1 may be involved in the
development of BE-associated malignancies. Given its ap-
parent abundant expression in BE with varying degrees of
dysplasia, but decreased expression in AC, it appears that
loss of TFF-1 expression may be one of the genetic alter-
ations encountered in the transition to invasive AC. This
finding has potential important biologic as well as practical
implications on the controversial issue of treatment of
patients with BE and HGD. Management of such individuals
can consist either of aggressive medical therapy and sur-
veillance endoscopy in some centers, or automatic refer-
ral for esophagectomy in others. The use of a biomarker
Table 3. Immunohistochemistry Scores of Tissue Microarrays of Adenocar-
cinomas by Anatomic Site of Origin.
IHC Score ‘‘Negative-to-
weak’’ 0 + 1 (%)
‘‘Moderate-to-
marked’’ 2 + 3 (%)
TFF-1 staining
Esophagus (n = 31) 24 (80.0%) 6 (20.0%)
EG Jxn (n = 72) 62 (78.5%) 17 (21.5%)
Stomach (n = 103) 96 (84.2%) 18 (15.8%)
CES-2 staining
Esophagus (n = 28) 13 (46.4%) 15 (53.6%)
EG Jxn (n = 80) 33 (41.3%) 47 (58.7%)
Stomach (n = 115) 51 (42.2%) 70 (57.8%)
Figure 3. Immunohistochemical analysis. Immunohistochemistry staining of trefoil factor 1 (TFF-1), microsomal aminopeptidase (CD-13), and Carboxylesterase 2
(CES-2) in representative specimens of normal esophagus, normal stomach, Barrett’s esophagus, Barrett’s esophagus with dysplasia, and adenocarcinoma.
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such as loss of TFF-1 may aid in the ability to predict the
likelihood of progression to malignancy in these patients,
and help guide treatment decisions in the future. Valida-
tion studies are planned to demonstrate this potential cli-
nical utility.
CES-2
As predicted by the microarray analysis, overexpression
of CES-2 protein product in BE was confirmed by IHC. In
addition, a major fraction (57.5%) of AC demonstrated
significant expression of CES-2. Noteworthy, of the AC
specimens that definitively arose in association with BE,
78.3% demonstrated abundant expression of CES-2. This
was statistically significantly higher than that seen with AC
specimens for which association with BE had not been
established (46.2%) (P = .022). These results suggest that
the differentiation of normal stratified squamous esophageal
mucosa into BE is accompanied by increased expression of
CES-2. In addition, it appears that CES-2 continues to be
overexpressed in a substantial majority of AC that arise from
BE. To our knowledge, this is the first report of CES-2 being
preferentially expressed in malignancies known to occur in
association with BE.
CES-2 is a hydrolytic enzyme present in a wide variety of
organs and tissues. The highest expression is seen in cells
of the liver, small intestine, adrenal cortex, and renal proxi-
mal tubule [22]. It has also been identified as the key
enzyme in the conversion of the chemotherapeutic agent
irinotecan—currently utilized in the treatment of malignan-
cies such as colorectal and gastric AC—into its active
metabolite. Recent literature suggests that expression of
CES-2 in target tumor tissue may correlate with the efficacy
of irinotecan therapy [49].
Thus, the presence of CES-2 expression in cancers
known to have developed in the setting of BE may ultimately
be utilized as a guide for the use of, and predictor of
therapeutic response to, irinotecan. This could be particularly
applicable in patients with esophageal, EGJ, or proximal
gastric AC who are at high risk for complications from
surgical intervention, and in whom chemotherapy, external
beam radiation, and therapeutic endoscopy are currently
the only available treatment options, with limited efficacy.
Once validated for clinical utility, CES-2 expression in BE-
associated cancers may add to our armamentarium to com-
bat this lethal disease.
Conclusions
This comprehensive utilization of microarray technology
to study BE, ACs that arise from this lesion, and normal tis-
sues has facilitated the identification of signature gene
expression alterations in these cases for further characteri-
zation. The analysis examined the expression of over
22,000 sequences in 38 specimens from all relevant tis-
sue subtypes, including normal epithelium and xeno-
grafted tumors, for optimal samples to analyze molecularly.
Furthermore, confirmatory analysis was performed, with
IHC utilizing TMAs containing nearly 300 tissue specimens
of tumors from various sites and pathologic stages from
four institutions.
BE-associated AC is a significant source of expense,
morbidity, and mortality in developed nations. Further knowl-
edge of the molecular mechanisms responsible for the
metaplasia-to-neoplasia sequence may lead to improved
understanding of this disease and, eventually, better out-
comes. The results of this study reveal novel, enticing find-
ings regarding the unique molecular profile of BE as it
compares with normal epithelial tissue and AC of the esoph-
agus, EGJ, and stomach. Future analyses are planned to
validate potential biomarkers such as TFF-1 and CES-2 in
more expanded studies.
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